Theranostics with Ga-68 Somatostatin Receptor PET/CT Monitoring Response to Peptide Receptor Radionuclide Therapy

被引：22

作者：

Kulkarni, Harshad R. ^{[1
]}

Baum, Richard P. ^{[1
]}

机构：

[1] Zen tralklin Bad Berka, THERANOSTICS Ctr Mol Radiotherapy & Mol Imaging, ENETS Ctr Excellence, D-99437 Bad Berka, Germany

来源：

PET CLINICS | 2014年 / 9卷 / 01期

关键词：

Somatostatin Receptors; Theranostics; Response;

D O I：

10.1016/j.cpet.2013.08.016

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Peptide receptor radionuclide therapy involves selective targeting of neuroendocrine tumors through somatostatin receptors with the aim to increase radiation dose to the tumors and spare normal tissue. The advantage of this internal radiation therapy is the ability to selectively target multiple metastases throughout the body. Early and accurate assessment of therapy response helps not only to identify the poor responders but also to personalize the treatment regimes with the aim of achieving maximum treatment benefit. This is the basis of theranostics.

引用

页码：91 / +

页数：8

共 16 条

[1]

Adams S, 1998, EUR J NUCL MED, V25, P79

[2] Circulating Biomarkers in Neuroendocrine Tumors of the Enteropancreatic Tract: Application to Diagnosis, Monitoring Disease, and as Prognostic Indicators [J].

Ardill, Joy E. S. ;

O'Dorisio, Thomas M. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2010, 39 (04) :777-+

[3]

Baum R. P., 2008, V170, P225

[4] Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Carreras, Cecilia .

SEMINARS IN NUCLEAR MEDICINE, 2012, 42 (03) :190-207

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6] 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy [J].

Gabriel, Michael ;

Oberauer, Andreas ;

Dobrozemsky, Georg ;

Decristoforo, Clemens ;

Putzer, Daniel ;

Kendler, Dorota ;

Uprimny, Christian ;

Kovacs, Peter ;

Bale, Reto ;

Virgolini, Irene J. .

JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (09) :1427-1434

[7] Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors [J].

Garin, Etienne ;

Le Jeune, Florence ;

Devillers, Anne ;

Cuggia, Marc ;

de Lajarte-Thirouard, Anne-Sophie ;

Bouriel, Catherine ;

Boucher, Eveline ;

Raoul, Jean-Luc .

JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) :858-864

[8] 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors [J].

Haug, Alexander R. ;

Auernhammer, Christoph J. ;

Waengler, Bjoern ;

Schmidt, Gerwin P. ;

Uebleis, Christopher ;

Goeke, Burkhard ;

Cumming, Paul ;

Bartenstein, Peter ;

Tiling, Reinhold ;

Hacker, Marcus .

JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) :1349-1360

[9]

Kulkarni HR, 2013, J NUCL MED, V54, P197

[10] The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors [J].

Lawrence, Ben ;

Gustafsson, Bjorn I. ;

Kidd, Mark ;

Pavel, Marianne ;

Svejda, Bernhard ;

Modlin, Irvin M. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (01) :111-+

← 1 2 →